ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Keryx Biopharmaceuticals, Inc." (KERX) Report Updated: May 23, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Keryx Biopharmaceuticals, Inc." (KERX)

Rating: Hold Volatility: Aggressive
Total Grade: C Industry: Biotechnology
Competitors: EBS,LOXO,EXEL,FPRX

Stock Analysis

Rating: Monthly View

A
B
C
D
F
May June July August September October November December January February March April

Rating: Weekly View

This Week: C down upgrade
Last Week: D same downgrade
Two Weeks Ago: C up upgrade
service keys

"Keryx Biopharmaceuticals, Inc."© quotemedia

Company Profile

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, as well as treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. The company also has sublicense agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has strategic alliance with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.